ValiRx (LON:VAL) has been granted patent protection in Australia for VAL201, its lead therapeutic compound that targets at a range of cancers.
The company already has full, worldwide rights and control over the commercialisation and development of potential treatments but said the new patent will enable it to extend its current patent protection and add to its portfolio.
VAL201 was licensed from Cancer Research Technology for use in androgen resistant cancer, an agreement that also included rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories.
Dr Satu Vainikka, chief executive, said: "The granting of this latest patent means that ValiRx is able to add to the company's intellectual property assets and extend its already extensive IP protection for this compound and its intended indications."
Early stage studies for VAL201 have shown encouraging signs that the compound inhibits aggressive tumour growth in prostate, breast and ovarian cancer as well as addressing endometriosis in women.
